GlassScriptPhysician profile
Julia Nellamattom
NPI 1730890468
$1,594.36
in general payments reported to CMS, 2019-2025
27 companies · $777 in 2025
The $777 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $251 · 2024: $567 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $267.60 | 2024-2025 | |
| Novo Nordisk INC | $233.44 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $122.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Viiv Healthcare Company | $83.85 | 2024-2025 | Apretude |
| Gilead Sciences, INC. | $78.05 | 2025 | |
| Corium, LLC | $75.30 | 2024-2025 | Azstarys |
| Lilly USA, LLC | $65.44 | 2024-2025 | Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $60.83 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $50.69 | 2024 | |
| Pfizer INC. | $46.23 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.90 | 2023-2024 | |
| Amgen INC. | $44.78 | 2024-2025 | Otezla, Repatha, Otezla |
| Collegium Pharmaceutical, INC. | $42.60 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $41.21 | 2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $41.14 | 2024 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $39.02 | 2025 | Andembry |
| Idorsia Pharmaceuticals US INC | $38.75 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $38.49 | 2025 | Xelstrym |
| Dexcom, INC. | $32.27 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $27.02 | 2023 | Aptima |
| Astrazeneca Pharmaceuticals LP | $23.85 | 2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $18.76 | 2025 | Rexulti |
| Coopersurgical, INC. | $17.27 | 2023 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $16.73 | 2023 | |
| Esperion Therapeutics, INC. | $16.59 | 2025 | Nexletol |
| Lundbeck LLC | $14.29 | 2023 | Rexulti |
| Organon LLC | $13.03 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Nellamattom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.